Get the Stockscreener App
11.32
1.89%
0.21
After Hours:
11.32
Keros Therapeutics Inc stock is traded at $11.32, with a volume of 65,634.
It is up +1.89% in the last 24 hours and up +10.44% over the past month.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
See More
Previous Close:
$11.11
Open:
$11.03
24h Volume:
65,634
Relative Volume:
0.28
Market Cap:
$224.44M
Revenue:
$33.18M
Net Income/Loss:
$-85.15M
P/E Ratio:
-3.7666
EPS:
-3.0054
Net Cash Flow:
$-58.25M
1W Performance:
+2.63%
1M Performance:
+10.44%
6M Performance:
-17.79%
1Y Performance:
-27.20%
1-Day Range:
$11.02
$11.40
1-Week Range:
$10.76
$11.49
52-Week Range:
$9.69
$22.55
Keros Therapeutics Inc Stock (KROS) Company Profile
Name
Keros Therapeutics Inc
Sector
Industry
Phone
617-314-6297
Address
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Compare KROS vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
11.32 | 217.11M | 33.18M | -85.15M | -58.25M | -3.0054 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Jun-10-25 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-21-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-17-25 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-16-24 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-16-24 | Reiterated | Oppenheimer | Outperform |
| Dec-13-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-12-24 | Downgrade | BTIG Research | Buy → Neutral |
| Dec-12-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-12-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-05-24 | Initiated | Jefferies | Buy |
| Oct-24-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-23-24 | Initiated | Guggenheim | Buy |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Feb-21-24 | Initiated | William Blair | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Jul-31-23 | Initiated | Wedbush | Outperform |
| Jul-26-23 | Initiated | BofA Securities | Buy |
| Feb-14-23 | Initiated | Cowen | Outperform |
| Oct-18-22 | Initiated | Truist | Buy |
| Jul-26-22 | Initiated | BTIG Research | Buy |
| Dec-08-20 | Reiterated | H.C. Wainwright | Buy |
| May-04-20 | Initiated | H.C. Wainwright | Buy |
| May-04-20 | Initiated | Jefferies | Buy |
| May-04-20 | Initiated | Piper Sandler | Overweight |
| May-04-20 | Initiated | SVB Leerink | Outperform |
View All
Keros Therapeutics Inc Stock (KROS) Latest News
Keros Therapeutics (NASDAQ:KROS) Downgraded by Wall Street Zen to "Strong Sell" - MarketBeat
Keros Therapeutics (NASDAQ:KROS): Is Its Pipeline Worth the Risk? - Kalkine Media
Empowered Funds LLC Makes New Investment in Keros Therapeutics, Inc. $KROS - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Understanding the Setup: (KROS) and Scalable Risk - news.stocktradersdaily.com
Keros Therapeutics director Bienaime buys $10,270 in shares By Investing.com - Investing.com South Africa
Keros Therapeutics director Bienaime buys $10,270 in shares - Investing.com
Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report? - Yahoo Finance
Man Group plc Purchases Shares of 155,541 Keros Therapeutics, Inc. $KROS - MarketBeat
BlackRock Inc. Buys Shares of 2,794,217 Keros Therapeutics, Inc. $KROS - MarketBeat
127,885 Shares in Keros Therapeutics, Inc. $KROS Purchased by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
Nantahala Capital Management LLC Takes Position in Keros Therapeutics, Inc. $KROS - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Upgraded to "Hold" at Zacks Research - MarketBeat
Keros Therapeutics director Bienaime buys $10,270 of KROS stock By Investing.com - Investing.com India
Keros Therapeutics director Bienaime buys $10,270 of KROS stock - Investing.com
ADAR1 Capital Management LLC Acquires New Position in Keros Therapeutics, Inc. $KROS - MarketBeat
Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk? - The Globe and Mail
Lorena Raquel Lerner Sells 3,568 Shares of Keros Therapeutics (NASDAQ:KROS) Stock - MarketBeat
Keros (KROS) Today: Moves 4.95% Down to $10.55 in the Latest Session; Market Levels: $10.02 and $11.08 Define the Nearby Reference Levels in the Available RecordPut Support - vinanet.vn
Keros Therapeutics CEO Showcases Breakthrough TGF-ß Platform at Major Goldman Sachs Healthcare Event - Stock Titan
Keros Therapeutics (NASDAQ: KROS) director schedules 551-share sale - Stock Titan
Keros Therapeutics Secures $20 Million Milestone Payment From Takeda - sekbernews.id
Keros Therapeutics (NASDAQ:KROS) Lowered to Strong Sell Rating by Wall Street Zen - MarketBeat
Keros Therapeutics (KROS) Drops 5.25% to $10.1 — Support at $9.59 in FocusEarnings Miss Risk - vinanet.vn
Can Keros Therapeutics (KROS)’s $20M Takeda Pharmaceutical Company Limited (TAK) Milestone Unlock a Billion-Dollar Opportunity? - Yahoo Finance
Understanding Momentum Shifts in (KROS) - Stock Traders Daily
Keros Therapeutics, Inc. $KROS Shares Acquired by Dimensional Fund Advisors LP - MarketBeat
Keros Therapeutics, Inc. Stock 12‑Month Price Target Cut to $19.83, Implies 86% Upside - TradingView
BofA Securities Adjusts Keros Therapeutics Price Target to $17 From $20 - marketscreener.com
KROS Q2 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage Investment CostsRevenue Warning Signal - vinanet.vn
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Rating of "Hold" by Analysts - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Raised to "Sell" at Wall Street Zen - MarketBeat
Renaissance Technologies LLC Sells 138,204 Shares of Keros Therapeutics, Inc. $KROS - MarketBeat
Keros Therapeutics, Inc. (KROS) Stock Analysis: Unveiling a 90.92% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment - qz.com
FY2026 EPS Estimate for Keros Therapeutics Raised by Analyst - MarketBeat
KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus - The Globe and Mail
KROS Maintained by Wells Fargo -- Price Target Lowered to $18.00 - GuruFocus
Leerink Partners Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $23 - Moomoo
Keros Therapeutics (NASDAQ:KROS) Price Target Lowered to $23.00 at Leerink Partners - MarketBeat
Keros Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
KEROS THERAPEUTICS INC : LEERINK PARTNERS CUTS TARGET PRICE TO $23 FROM $30 - Bitget
Keros Therapeutics (NASDAQ:KROS) Announces Quarterly Earnings Results, Misses Estimates By $0.20 EPS - MarketBeat
Keros Therapeutics 2026: Revenue $0 EPS ($1.45) — 10-Q Summary - TradingView
Keros Therapeutics Reports Second Quarter 2026 Financial Results - The Manila Times
Keros Therapeutics posts $28.7 million second quarter net loss - Quiver Quantitative
KROS: Reduced net loss and strong cash position support ongoing clinical progress into 2028 - TradingView
Avoiding Lag: Real-Time Signals in (KROS) Movement - Stock Traders Daily
KROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026? - qz.com
Keros Therapeutics, Inc. (KROS) Stock Analysis: Navigating a 113.63% Potential Upside in Biotechnology - DirectorsTalk Interviews
Keros Therapeutics (NASDAQ:KROS) Lowered to Strong Sell Rating by Zacks Research - MarketBeat
Keros Therapeutics Inc Stock (KROS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Keros Therapeutics Inc Stock (KROS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lerner Lorena Raquel | Chief Scientific Officer |
Aug 18 '26 |
Sale |
10.29 |
3,568 |
36,715 |
27,559 |
| Cho Esther | Chief Legal Officer |
Aug 18 '26 |
Sale |
10.29 |
4,485 |
46,151 |
35,770 |
| Newton Charles W. | Director |
Aug 18 '26 |
Sale |
10.30 |
551 |
5,675 |
12,114 |
| BIENAIME JEAN JACQUES | Director |
Aug 17 '26 |
Buy |
10.27 |
1,000 |
10,270 |
19,592 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):